NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 127 filers reported holding NURIX THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $142,248 | – | 14,239 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP III, LLC | 3,422,549 | $90,800,000 | 15.85% |
| Ponoi II Management, LLC | 686,274 | $18,207,000 | 14.76% |
| Ponoi Management, LLC | 686,274 | $18,207,000 | 10.12% |
| Foresite Capital Management V, LLC | 451,522 | $11,979,000 | 4.71% |
| Foresite Capital Management IV, LLC | 1,205,798 | $31,990,000 | 4.32% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $34,073,000 | 2.23% |
| EcoR1 Capital, LLC | 1,967,950 | $52,210,000 | 1.95% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $15,155,000 | 1.93% |
| DAFNA Capital Management LLC | 306,320 | $8,127,000 | 1.70% |
| Euclidean Capital LLC | 154,426 | $4,097,000 | 1.33% |